Quarterly ResultAug 12, 2026, 04:25 PM
Allogene Therapeutics Q2 Net Loss Narrows to $42.7M
AI Summary
Allogene Therapeutics reported a net loss of $42.7 million for Q2 2026, narrowing from $50.9 million in Q2 2025, and a net loss of $85.3 million for the first six months of 2026, down from $110.7 million year-over-year. The company significantly bolstered its financial position by raising approximately $208.6 million through ATM and public equity offerings, bringing its total cash, cash equivalents, and investments to $423.6 million as of June 30, 2026. This capital is expected to fund operations for at least the next 12 months, despite ongoing cumulative net losses of $2.1 billion since inception and potential impacts from a legal dispute concerning its Cellectis and Servier agreements.
Key Highlights
- Q2 2026 net loss was $42.7 million, an improvement from $50.9 million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.13), compared to $(0.23) in Q2 2025.
- Raised $187.9 million net from an April 2026 public offering of 100.2 million shares.
- Raised $20.7 million net from ATM offerings during the first six months of 2026.
- Cash, cash equivalents, and investments totaled $423.6 million as of June 30, 2026.
- Net cash used in operating activities decreased to $44.9 million in H1 2026 from $92.0 million in H1 2025.
- Cumulative net losses since inception reached $2.1 billion as of June 30, 2026.
- Evaluating potential impact of arbitration between LTC and Cellectis on licensing rights.
Price Impact
More from ALLO